Characterization of Mycobacterium paratuberculosis p36 antigen and its seroreactivities in Crohn's disease

F A El-Zaatari1, S A Naser, K Hulten

  • 1Inflammatory Bowel Disease Laboratory, Veterans Affairs Medical Center, 2002 Holcombe Blvd., Houston, TX 77030, USA.

Current Microbiology
|July 10, 1999
PubMed

Insights

This study investigated Mycobacterium paratuberculosis in Crohn's disease (CD). High antibody reactivity to a novel M. paratuberculosis antigen (p36) in CD patients supports a potential mycobacterial cause for this inflammatory bowel disease.

Area of Science:

  • Microbiology
  • Immunology
  • Gastroenterology

Background:

  • Crohn's disease (CD) is an inflammatory bowel disease (IBD) with an unknown cause.
  • Emerging evidence suggests a potential link between Mycobacterium paratuberculosis and CD.

Purpose of the Study:

  • To investigate antibody responses to M. paratuberculosis antigens in CD patients.
  • To identify novel mycobacterial antigens associated with CD.

Main Methods:

  • Analysis of a novel M. paratuberculosis antigen (p36) using immunoblotting.
  • Testing serum reactivity against p36 in patients with CD, ulcerative colitis, tuberculosis, leprosy, and healthy controls.

Main Results:

  • A novel M. paratuberculosis antigen, p36, showed high reactivity with sera from 86.5% of CD patients.
  • Sera from tuberculosis and leprosy patients also showed high reactivity to p36.
  • Low reactivity was observed in ulcerative colitis and non-IBD controls (12%).
  • BCG-immunized controls showed high reactivity, while non-immunized controls showed low reactivity.

Conclusions:

  • The high frequency of antibody reactivity to p36 in CD patients supports a mycobacterial etiology for Crohn's disease.
  • p36 represents a novel mycobacterial antigen potentially involved in the pathogenesis of CD.

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...